
Wilhelm Krek

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11621157/publications.pdf Version: 2024-02-01



WILLELM KDEK

#	Article	IF	CITATIONS
1	Identification of HIF-dependent alternative splicing in gastrointestinal cancers and characterization of a long, coding isoform of SLC35A3. Genomics, 2021, 113, 515-529.	1.3	4
2	A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of <i>BRAF</i> -mutated Melanoma to MAPK Inhibitors. Clinical Cancer Research, 2019, 25, 6852-6867.	3.2	74
3	BRAF inhibition sensitizes melanoma cells to α-amanitin via decreased RNA polymerase II assembly. Scientific Reports, 2019, 9, 7779.	1.6	9
4	Inhibition of the Hypoxia-Inducible Factor 1α–Induced Cardiospecific HERNA1 Enhance-Templated RNA Protects From Heart Disease. Circulation, 2019, 139, 2778-2792.	1.6	26
5	NGS-pipe: a flexible, easily extendable and highly configurable framework for NGS analysis. Bioinformatics, 2018, 34, 107-108.	1.8	25
6	Fructose metabolism, cardiometabolic risk, and the epidemic of coronary artery disease. European Heart Journal, 2018, 39, 2497-2505.	1.0	64
7	Correction of gene model annotations improves isoform abundance estimates: the example of ketohexokinase (Khk). F1000Research, 2018, 7, 1956.	0.8	5
8	Correction of gene model annotations improves isoform abundance estimates: the example of ketohexokinase (Khk). F1000Research, 2018, 7, 1956.	0.8	7
9	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	4.3	4,701
10	jSplice: a high-performance method for accurate prediction of alternative splicing events and its application to large-scale renal cancer transcriptome data. Bioinformatics, 2016, 32, 2111-2119.	1.8	10
11	Hypoxia-driven glycolytic and fructolytic metabolic programs: Pivotal to hypertrophic heart disease. Biochimica Et Biophysica Acta - Molecular Cell Research, 2016, 1863, 1822-1828.	1.9	42
12	Colorectal cancer cells display chaperone dependency for the unconventional prefoldin URI1. Oncotarget, 2016, 7, 29635-29647.	0.8	16
13	Integrated genomic analysis identifies subclasses and prognosis signatures of kidney cancer. Oncotarget, 2015, 6, 10521-10531.	0.8	42
14	HIF-driven SF3B1 induces KHK-C to enforce fructolysis and heart disease. Nature, 2015, 522, 444-449.	13.7	144
15	Tumor Suppressor VHL Functions in the Control of Mitotic Fidelity. Cancer Research, 2014, 74, 2422-2431.	0.4	27
16	HIF1Î \pm deubiquitination by USP8 is essential for ciliogenesis in normoxia. EMBO Reports, 2014, 15, 77-85.	2.0	64
17	<scp>KPNA2</scp> is overexpressed in human and mouse endometrial cancers and promotes cellular proliferation. Journal of Pathology, 2014, 234, 239-252.	2.1	23
18	3D cell culture systems modeling tumor growth determinants in cancer target discovery. Advanced Drug Delivery Reviews, 2014, 69-70, 29-41.	6.6	369

WILHELM KREK

#	Article	IF	CITATIONS
19	Tumor Suppressor NF2/Merlin Is a Microtubule Stabilizer. Cancer Research, 2014, 74, 353-362.	0.4	19
20	miR-28-5p Promotes Chromosomal Instability in <i>VHL</i> -Associated Cancers by Inhibiting Mad2 Translation. Cancer Research, 2014, 74, 2432-2443.	0.4	44
21	Hif-2α Promotes Degradation of Mammalian Peroxisomes by Selective Autophagy. Cell Metabolism, 2014, 20, 882-897.	7.2	131
22	The protein tyrosine phosphatase receptor type J is regulated by the <scp>pVHL–HIF</scp> axis in clear cell carcinoma. Journal of Pathology, 2013, 229, 525-534.	2.1	11
23	The Hypoxia-Inducible MicroRNA Cluster miR-199aâ^1⁄4214 Targets Myocardial PPARδ and Impairs Mitochondrial Fatty Acid Oxidation. Cell Metabolism, 2013, 18, 341-354.	7.2	193
24	A High-Throughput–Compatible 3D Microtissue Co-Culture System for Phenotypic RNAi Screening Applications. Journal of Biomolecular Screening, 2013, 18, 1330-1337.	2.6	45
25	Combined mutation of <i>Vhl</i> and <i>Trp53</i> causes renal cysts and tumours in mice. EMBO Molecular Medicine, 2013, 5, 949-964.	3.3	131
26	Loss of PBRM1 expression is associated with renal cell carcinoma progression. International Journal of Cancer, 2013, 132, E11-7.	2.3	139
27	Genetic deletion of the long isoform of the von Hippel–Lindau tumour suppressor gene product alters microtubule dynamics. European Journal of Cancer, 2013, 49, 2433-2440.	1.3	12
28	Dietary obesity-associated Hif1α activation in adipocytes restricts fatty acid oxidation and energy expenditure via suppression of the Sirt2-NAD ⁺ system. Genes and Development, 2012, 26, 259-270.	2.7	264
29	Identification and Functional Characterization of pVHL-Dependent Cell Surface Proteins in Renal Cell Carcinoma. Neoplasia, 2012, 14, 535-IN17.	2.3	44
30	p53 suppresses type II endometrial carcinomas in mice and governs endometrial tumour aggressiveness in humans. EMBO Molecular Medicine, 2012, 4, 808-824.	3.3	60
31	Novel Prognostic Markers in the Serum of Patients With Castration-Resistant Prostate Cancer Derived From Quantitative Analysis of the Pten Conditional Knockout Mouse Proteome. European Urology, 2011, 60, 1235-1243.	0.9	49
32	URI Is an Oncogene Amplified in Ovarian Cancer Cells and Is Required for Their Survival. Cancer Cell, 2011, 19, 317-332.	7.7	77
33	Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 3342-3347.	3.3	175
34	PKA phosphorylates and inactivates AMPKα to promote efficient lipolysis. EMBO Journal, 2010, 29, 469-481.	3.5	235
35	Analysis of microtubule dynamic instability using a plus-end growth marker. Nature Methods, 2010, 7, 761-768.	9.0	222
36	Quantitative image analysis identifies pVHL as a key regulator of microtubule dynamic instability. Journal of Cell Biology, 2010, 190, 991-1003.	2.3	48

WILHELM KREK

#	Article	IF	CITATIONS
37	Double-trouble in mitosis caused by von Hippel-Lindau tumor-suppressor protein inactivation. Cell Cycle, 2009, 8, 3619-3620.	1.3	5
38	Sporadic clear cell renal cell carcinoma but not the papillary type is characterized by severely reduced frequency of primary cilia. Modern Pathology, 2009, 22, 31-36.	2.9	104
39	VHL loss causes spindle misorientation and chromosome instability. Nature Cell Biology, 2009, 11, 994-1001.	4.6	141
40	Activation of a HIF11±-PPAR1³ Axis Underlies the Integration of Glycolytic and Lipid Anabolic Pathways in Pathologic Cardiac Hypertrophy. Cell Metabolism, 2009, 9, 512-524.	7.2	342
41	pVHL and PTEN tumour suppressor proteins cooperatively suppress kidney cyst formation. EMBO Journal, 2008, 27, 1747-1757.	3.5	138
42	pVHL: A Multipurpose Adaptor Protein. Science Signaling, 2008, 1, pe30.	1.6	81
43	Essential Role of Developmentally Activated Hypoxia-Inducible Factor 1α for Cardiac Morphogenesis and Function. Circulation Research, 2008, 103, 1139-1146.	2.0	112
44	Combined <i>Vhlh</i> and <i>Pten</i> Mutation Causes Genital Tract Cystadenoma and Squamous Metaplasia. Molecular and Cellular Biology, 2008, 28, 4536-4548.	1.1	41
45	pVHL is a regulator of glucose metabolism and insulin secretion in pancreatic \hat{I}^2 cells. Genes and Development, 2008, 22, 3135-3146.	2.7	88
46	The VHL Tumor Suppressor: Riding Tandem with GSK3β in Primary Cilium Maintenance. Cell Cycle, 2007, 6, 1809-1813.	1.3	55
47	S6K1-Mediated Disassembly of Mitochondrial URI/PP1γ Complexes Activates a Negative Feedback Program that Counters S6K1 Survival Signaling. Molecular Cell, 2007, 28, 28-40.	4.5	101
48	pVHL and GSK3β are components of a primary cilium-maintenance signalling network. Nature Cell Biology, 2007, 9, 588-595.	4.6	220
49	Multitasking by pVHL in tumour suppression. Current Opinion in Cell Biology, 2007, 19, 685-690.	2.6	61
50	URI-1 is required for DNA stability in C. elegans. Development (Cambridge), 2006, 133, 621-629.	1.2	56
51	Priming-Dependent Phosphorylation and Regulation of the Tumor Suppressor pVHL by Glycogen Synthase Kinase 3. Molecular and Cellular Biology, 2006, 26, 5784-5796.	1.1	72
52	Regulation of p27 Degradation and S-Phase Progression by Ro52 RING Finger Protein. Molecular and Cellular Biology, 2006, 26, 5994-6004.	1.1	68
53	The HRPT2 Tumor Suppressor Gene Product Parafibromin Associates with Human PAF1 and RNA Polymerase II. Molecular and Cellular Biology, 2005, 25, 5052-5060.	1.1	184
54	The von Hippel–Lindau tumour suppressor: a multi-faceted inhibitor of tumourigenesis. Trends in Molecular Medicine, 2004, 10, 466-472.	3.5	65

WILHELM KREK

#	Article	IF	CITATIONS
55	Chemokine receptor CXCR4 downregulated by von Hippel–Lindau tumour suppressor pVHL. Nature, 2003, 425, 307-311.	13.7	845
56	Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL. Nature Cell Biology, 2003, 5, 64-70.	4.6	309
57	Relevance of Nuclear and Cytoplasmic von Hippel Lindau Protein Expression for Renal Carcinoma Progression. American Journal of Pathology, 2003, 163, 1013-1020.	1.9	34
58	Control of Nutrient-Sensitive Transcription Programs by the Unconventional Prefoldin URI. Science, 2003, 302, 1208-1212.	6.0	164
59	A CDK-Independent Function of Mammalian Cks1. Molecular Cell, 2001, 7, 639-650.	4.5	345
60	Induction of hepatocyte proliferation and liver hyperplasia by the targeted expression of cyclin E and skp2. Oncogene, 2001, 20, 1825-1831.	2.6	47
61	Metabolic stabilization of p27 in senescent fibroblasts correlates with reduced expression of the F-box protein Skp2. Experimental Gerontology, 2001, 37, 41-55.	1.2	27
62	p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells. Nature Cell Biology, 1999, 1, 207-214.	4.6	647
63	Loss of Cul1 results in early embryonic lethality and dysregulation of cyclin E. Nature Genetics, 1999, 23, 245-248.	9.4	164
64	Association of Human SCFSKP2Subunit p19SKP1with Interphase Centrosomes and Mitotic Spindle Poles. Experimental Cell Research, 1999, 247, 554-562.	1.2	52
65	Proteolysis and the G1-S transition: the SCF connection. Current Opinion in Genetics and Development, 1998, 8, 36-42.	1.5	154
66	Cyclin A-Kinase Binding to and Regulation of the Function of a Growth-Promoting Transcription Factor. , 1996, , 193-199.		0
67	Cyclin A-kinase regulation of E2F-1 DNA binding function underlies suppression of an S phase checkpoint. Cell, 1995, 83, 1149-1158.	13.5	349
68	Expression cloning of a cDNA encoding a retinoblastoma-binding protein with E2F-like properties. Cell, 1992, 70, 351-364.	13.5	916